Epigenetic regulations play crucial roles in leukemogenesis and leukemia progression. SUV39H1 is the dominant H3K9 methyltransferase in the hematopoietic system, and its expression declines with aging. However, the role of SUV39H1 via its-mediated repressive modification H3K9me3 in leukemogenesis/leukemia progression remains to be explored. We found that SUV39H1 was down-regulated in a variety of leukemias, including MLL-r AML, as compared with normal individuals. Decreased levels of Suv39h1 expression and genomic H3K9me3 occupancy were observed in LSCs from MLL-r-induced AML mouse models in comparison with that of hematopoietic stem/progenitor cells. Suv39h1 overexpression increased leukemia latency and decreased the frequency of LSCs in MLL-r AML mouse models, while Suv39h1 knockdown accelerated disease progression with increased number of LSCs. Increased Suv39h1 expression led to the inactivation of Hoxb13 and Six1, as well as reversion of Hoxa9/Meis1 downstream target genes, which in turn decelerated leukemia progression. Interestingly, Hoxb13 expression is up-regulated in MLL-AF9-induced AML cells, while knockdown of Hoxb13 in MLL-AF9 leukemic cells significantly prolonged the survival of leukemic mice with reduced LSC frequencies. Our data revealed that SUV39H1 functions as a tumor suppressor in MLL-AF9-induced AML progression. These findings provide the direct link of SUV39H1 to AML development and progression.
Acute myeloid leukemia (AML) is the most frequent type of acute leukemia in adults. However, there have been few significant advances in the past 40 years beyond the use of conventional chemotherapy in combination with bone marrow (BM) transplantation for AML treatment [1, 2]. Therefore, investigating the underlying mechanisms of AML initiation and progression is needed to find novel treating targets/strategies for AML.
Genome-wide analyses have shown that genes involved in epigenetic modifications are the most recurrently mutated genes in AML, suggesting crucial roles of epigenetic regulations in AML leukemogenesis and progression [3, 4]. These genes, including the methylcytosine hydroxylase TET2, DNA methyltransferase DNMT3A, and Polycomb-related protein ASXL1, directly contribute to the aberrant distribution of epigenetic modifications in AML .
Leukemia bearing translocations involving chromosome 11q23 is one of the most aggressive and drug-resistant leukemias, characterized by the presence of Mixed Lineage Leukemia (MLL) rearrangements. More than 79 fusion genes have been reported to translocate with MLL, sharing some correlation with disease phenotype and prognosis [6,7,8]. MLL-r leukemia exhibits a distinct characteristic of pathology and molecular mechanism from other subtypes of AML. It has been reported that MLL-r leukemia stem cells (LSCs) exhibits aberrantly increased levels of H3K4me3 and H3K79me2 [9,10,11,12,13]. The high level of H3K4me3 in LSC, due to the decreased expression of H3K4-specific demethylase KDM5B , was shown to be associated with LSC maintenance. In addition, the hyperactive H3K79 methyltransferase DOT1L has been reported to be responsible for the aberrant H3K79me2 in MLL-r leukemia [11, 13]. It was reported that the high levels of lysine-specific demethylase KDM1A (catalyzes the demethylation of H3K4me1/2 and H3K9me1/2) was essential for MLL-r induced leukemia . SUV39H1, the first characterized mammalian lysine methyltransferase, catalyzes the di- and tri-methylation of histone 3 lysine 9 . SUV39H1 is the predominant H3K9 methyltransferase expressed in mouse long-term hematopoietic stem cells (LT-HSCs), human cord blood cells and BM CD34+CD38– HSCs . Report showed that SUV39H1 expression declines with aging in human and mouse HSCs, leading to a global H3K9me3 reduction and perturbed heterochromatin function . These results suggest a tight connection of SUV39H1 with aging, which is considered as one of the strongest predisposition factors for myeloid malignancy . Interestingly, SUV39H1 has been reported to interact with Menin , which interacts with MLL-fusion proteins to promote oncogenesis [19, 20]. In MLL-r leukemic cells, Dot1L, via its binding to the DNA, interrupts the normal localization of Suv39h1 and Sirt1, and deletion of Suv39h1 desensitizes leukemic cells to Dot1L inhibition . In addition, Dot1L-mediated H3K79 methylation requires the predisposition of H3K9 acetylation, which is recognized by AF9 . These studies suggest that SUV39H1 plays a role in MLL-r AML.
Here we examined the expression patterns of SUV39H1 in MLL-r AML and normal hematopoietic cell populations, and its correlation with AML outcomes. We further dissected the role of SUV39H1 in MLL-r induced AML progression, and explored the underlying molecular pathways mediated by SUV39H1 in MLL-r AML progression. Our studies revealed a tumor suppressive role of Suv39h1 in MLL-r AML that is partially mediated by inactivation of Hoxb13 and Six1, as well as reversion of Hoxa9/Meis1 downstream transcriptomes.
Decreased expression of SUV39H1 in both human and mouse AML leukemia stem cells in comparison with their normal counterparts
To examine the potential clinical relevance of SUV39H1 to human AML, the expression pattern of SUV39H1 was assessed in two public AML databases in BloodSpot . SUV39H1 expression was significantly lower in a variety of leukemias, including the MLL-r AML, when compared with its expression in granulocyte-monocyte progenitor cells (GMPs) (Supplementary Fig. 1a) or with the nearest normal counterpart (Supplementary Fig. 1b), as recently published study . In addition, the expression level of SUV39H1 in stem/progenitor-enriched CD34+ AML cells was significantly lower than in normal cord blood CD34+ cells, which may either be due to the age effect  or the combinative effects of age and leukemia (Fig. 1a). We further explored the correlation between the expression level of SUV39H1 and patient survival data using PrognoScan  and found that there was a trend that higher level of SUV39H1 predicted better prognosis when patients were separated according to the median expression (Supplementary Fig. 1c–e). Using MLL-AF9 (MA9)-induced and MLL-NRIP3 (MN3)-induced AML mouse models, we further examined the expression level of Suv39h1 in murine LSCs in comparison with HSPCs. We found that Suv39h1 expression was reduced in both c-Kit+ defined LSCs  and L-GMP (labeled as Lin−Sca1−IL-7R−c-Kit+CD34+FcR-rII/III+) LSCs , as compared with their normal counterparts (Fig. 1b, c). These data suggest a potential role of Suv39h1 in AML maintenance.
Differential distributions of H3K9me3 in normal hematopoietic stem/progenitor cells and leukemia stem cells
Suv39h1 has been shown to be the most abundant H3K9 methyltransferase in HSPCs [16, 17]. This observation was confirmed by using droplet digital PCR for absolute quantification of H3K9 methyltransferases in c-Kit+ cells (Supplementary Fig. 1f). Since the aberrant distribution of H3K9me3 was observed widely in AML patients , we therefore, hypothesized that decreased expression of Suv39h1 may contribute to a reduction of genomic H3K9me3 occupancy in LSCs. To gain an overview of H3K9me3 occupancy in MLL-r AML, we performed H3K9me3 chromatin immunoprecipitation sequencing (ChIP-seq) in c-Kit+ cells from WT controls, MA9 and MN3 AML mice. The distributions of H3K9me3 on the whole genome and around TSS (transcriptional start site, defined as TSS ± 2 kb) were significantly lower in AML LSCs than in normal HSPCs (Fig. 1d, e and Supplementary Fig. 2a, b). Consistent with previous H3K9me3 ChIP-seq data in human peripheral blood mononuclear cells from ENCODE [GSM613878], the H3K9me3 peaks in the WT, MA9, and MN3 groups had a higher chance of being located in intergenic and intron regions (Supplementary Fig. 2c). Gene ontology (GO) analyses of the H3K9me3 differentially enriched genes revealed an involvement of several important signaling pathways mis-regulated in cancers (Supplementary Fig. 2d), suggesting a dysregulated distribution of H3K9me3 in leukemogenesis.
SUV39H1 expression levels affect the leukemic progression of MLL-AF9-induced AML
To delineate the role of SUV39H1 in MLL-r AML, we used a lentivirus-mediated transduction system to restore the expression of Suv39h1 in MA9 BM AML cells. MA9 leukemia cells isolated from quaternary recipients (P3 MA9 cells) that were infected with Suv39h1-overexpression lentivirus have been stably passaged for three times (Fig. 2a). Sorted eGFP+ cells were transplanted to sublethally-irradiated recipient mice (Supplementary Fig. 3a). Western blotting analysis confirmed the restored expression of Suv39h1 (about 1.7-fold increase than WT cells) with a moderate increase in global H3K9me3 levels in Suv39h1-overexpressed (SUV-OE) P2 cells (Fig. 2b). Consistent with qRT-PCR result (Fig. 1b), we observed a decrease of Suv39h1 in regular AML cells in comparison with normal BM cells (Fig. 2b). The stably passaged SUV OE MLL-AF9 leukemia cells are highly enriched with LSCs and rather malignant. Once transplanted, mice can quickly develop leukemia and died in a short period of time. To ensure that the survival experiment data of leukemic mice are more discernable and accurate, we chose two relatively low doses of leukemia cells (Cell No. 1 × 103 or 1 × 104) for transplantation in our study. Significantly, Suv39h1 overexpression prolonged the survival of secondary murine recipients (Fig. 2c, d), as well as in the tertiary recipients (Fig. 2e, f). Moreover, immunoblot analyses of SUV-OE MLL-AF9 leukemia cells (P1 and P2 cells) showed that overexpression of Suv39h1 increased H3K9 trimethylation level in the whole BM cells isolated from secondary and tertiary recipient mice (Supplementary Fig. 3b, c). Considering the crucial role of LSC in the initiation and maintenance of leukemia, we further analyzed the effect of Suv39h1 on LSCs in MA9 AML mouse model. As assessed by immunophenotype, the frequency and absolute number of c-Kit+ and L-GMP LSCs in BM and SP were significantly decreased in SUV-OE groups when compared with those in controls (Fig. 3a–d and Supplementary Fig. 3d). Functional analyses with limiting dilution assays revealed an approximately fivefold and sixfold decreases in LSC numbers in SUV-OE AML cells from primary and secondary recipients, respectively (Fig. 3e, f).
Restored expression of Suv39h1 induced apoptosis and suppressed proliferation of LSCs
The reduced frequency of LSCs by SUV-OE in MA9 AML mice prompted us to further investigate whether SUV-OE alters the apoptosis and cell cycle in LSCs. We observed a slightly increased percentage of apoptotic c-Kit+ and L-GMP LSCs in BM and SP in the SUV-OE mice group (Fig. 4a, b). Flow cytometry analysis of c-Kit+ LSCs from BM and SP revealed a significantly decreased proportion of cells at the S/G2/M phase and a concordant increased proportion of G0/G1 phases in SUV-OE c-Kit+ LSCs cells when compared with the proportions in control cells (Fig. 4c, d). Further analyses of the cell cycle status with either Ki67 staining or BrdU incorporation of L-GMP cells revealed similar results (Fig. 4e–g). Interestingly, since Ki67 is not expressed in G0 phase, we could distinguish that the increased G0/G1 phase is mainly due to the increased of G1 phase but not G0 phase. These data collectively showed that restoration of Suv39h1 expression level induces the apoptosis of LSCs and impairs the proliferation of LSCs.
To substantiate our in vivo observations in MLL-r murine model, we further restored the expression of SUV39H1 in human THP-1, Molm13 and Nomo-1 cell lines, which bearing the MLL fusion gene (Supplementary Fig. 4a–c). Colorimetric-based CCK8 assay showed that restoration of SUV39H1 expression significantly suppressed the cell growth in these three cell lines (Supplementary Fig. 4d–f) and the proliferation abilities of Nomo-1 cells (Supplementary Fig. 4g–j). Furthermore, the apoptotic ratios of SUV-OE cell lines were much higher than that of the controls (Supplementary Fig. 4k–p). In addition, Suv39h1 shRNA knockdown (Supplementary Fig. 4q, r) could promote the cell growth of THP-1 and Molm13 cells (Supplementary Fig. 4s, t) and cell cycling of Molm13 cells (Supplementary Fig. 4u, v) when compared with the controls. Collectively, these results suggest a tumor suppressive role of SUV39H1 in both MLL-r AML mouse model and human cell line.
Suppression of Suv39h1 accelerated the leukemic progression in MLL-AF9-induced AML
Chaetocin was the first reported inhibitor for SUV39H1/H2 , although the follow-up studies showed that this inhibition was not totally specific and time-dependent [30,31,32]. Recent study indicates a suppressive role of chaetocin in human AML cell lines and in a xenograft mouse model (none of these cell lines bearing MLL-r translocation as reported) [33, 34]. Since there isn’t a specific inhibitor of SUV39H1, we therefore used chaetocin to test the potential effect of this non-specific inhibitor of SUV39H1 in MA9 AML mouse models. We examined the effect of chaetocin treatment with different dosages and regimens during leukemia progression. First, sub-lethally irradiated mice were transplanted with 1 × 104 MA9 P2 AML cells, then treated with chaetocin or vehicle one day after transplantation (Fig. 5a). Shortened survivals were observed in low dosage (0.25 mg chaetocin /kg) group. A slightly accelerated disease progression was also observed in high dosage group (0.5 mg/kg, the same dosage as used in ref. ) (Fig. 5b). No obvious body weight changes were observed in low dosage group in comparison with vehicle group (Supplementary Fig. 5a). The same treatment but with lower input leukemia cells also showed accelerated disease progression when treated with chaetocin (Fig. 5c and Supplementary Fig. 5b). If chaetocin treatment started around 5% GFP+ cells in peripheral blood, no significant differences were observed between chaetocin and vehicle treatment group (Supplementary Fig. 5c–h). We confirmed that the level of H3K9me3 was decreased upon chaetocin (higher dose) treatment (Supplementary Fig. 5i, j).
Considering the non-direct effect of chaetocin on SUV39H1 [30,31,32], we further explored whether direct suppression of Suv39h1 would accelerate leukemia progression by reducing the expression of Suv39h1 using shRNA-mediated knockdown (Fig. 5d, e). Suv39h1 knockdown with shSUV-a accelerated the progression of leukemia with an average of 20.5-day survival in shSUV-a group vs. 23-day in scramble established in parallel with shSUV-a (Fig. 5f), and 26-day survival in shSUV-b group vs. 30.5-day in its parallel scramble (Fig. 5g). The effect of Suv39h1 knockdown on survival was further reconfirmed with simultaneously established scramble, shSuv-a, and shSuv-b groups. An average of 24-day survival in shSUV-a, 25-day survival in shSUV-b respectively vs. 28-day in scramble group were observed (Supplementary Fig. 6a, b). The levels of H3K9me3 were decreased accompanied with Suv39h1 knockdown (Supplementary Fig. 6c, d). In addition, the LSC frequencies measured by the colony-forming capacity assay, were increased in sh-SUV groups as compared with the controls (Fig. 5h, i). These data demonstrated that Suv39h1 is a critical regulator of leukemia progression in MLL-r AML.
Suv39h1 overexpression led to dysregulation of transcriptional program involved in leukemia
To examine the underlying mechanisms by which Suv39h1 restoration suppresses MLL-r leukemia progression, gene expression profiles were assessed using RNA-Seq in LSCs. A total of 684 genes were differentially expressed (|log2FC| ≥ 1 and FDR < 0.05). Among these genes, 158 were down-regulated, and 526 were upregulated (Fig. 6a, b). KEGG pathway analyses of these differentially expressed genes (DEG) showed enrichment of transcriptional mis-regulation in cancer, ECM-receptor interaction, hematopoietic cell lineage, and several signaling pathways, such as PI3K-Akt pathway, FOXO pathway and p53 pathway (Supplementary Fig. 7a). Most of these pathways were consistent with the differential H3K9me3 peaks in LSCs vs. HSCs (Supplementary Fig. 2d). The relationships between these enriched KEGG pathways of DEGs were further dissected with Cytoscape. These KEGG pathways primarily fell into two groups: one group contained up-regulated apoptosis as one of the most central pathways, and the other contained down-regulated metabolic pathways (Supplementary Fig. 7b). The upregulated apoptosis was consistent with the increased apoptosis phenotype in SUV-OE LSCs from MA9 AML mice (Fig. 4a, b). The dysregulated metabolic pathways might be due to the decreased expression of transcription factor Six1 (Fig. 6b, c), which was reported as a regulator of metabolism [35, 36].
Gene set enrichment analysis  demonstrated an increased expression of suppressed target genes by HOXA9 and MEIS1, and a decreased expression of the activated target genes by HOXA9 and MEIS1  in the SUV-OE group (Fig. 6d, e), suggesting a suppressive effect of Suv39h1 on HOXA9 and MEIS1 signature genes. A suppression of E2F targets was also observed in the SUV-OE group (Fig. 6f), which was consistent with the phenotype of suppression of cell proliferation with SUV-OE (Fig. 4c–e). In addition, we found Six1, one of the MA9 targets [11, 39], was among the top of DEGs. Using qRT-PCR, we further validated the differential expression of several DEGs implicated in leukemogenesis, including Six1, Hoxb13, Mlf1, Pax5 and Dntt (Fig. 6c). Genes involved in cell cycle regulation were also validated using qRT-PCR (Fig. 6g, h). These data indicated that Suv39h1 regulates leukemic transcriptional program in MLL-r leukemia.
Hoxb13 functions as a downstream effector of Suv39h1, and restoration of Hoxb13 neutralizes the effect of SUV-OE
Given the transcriptional suppressive role of Suv39h1 by maintaining the transcriptional repressive modification mark H3K9me3, we focused on genes with significantly decreased expression in SUV-OE vs. control AML c-Kit+ cells. Among those leukemia-associated genes mentioned above, Hoxb13 was of particular interesting because it is recurrently mutated in several types of cancers, including leukemia . H3K9me3 ChIP-qPCR revealed that the H3K9me3 level at the promoter of Hoxb13 was increased by twofold in SUV-OE groups (Fig. 7a), suggesting the decreased expression of Hoxb13 might be a direct effect of the acquisition of H3K9me3 modification. By restoration of the Hoxb13 expression in SUV-OE AML cells (Fig. 7b), we found an accelerated leukemia progression in SUV-OE AML mice, indicating that Hoxb13 restoration abolished the effect of SUV-OE on prolonged survival of MLL-r AML mice (Fig. 7c). Hoxb13 restoration also increased the colony formation capacity of SUV-OE cells (Fig. 7d). These data suggested a possible role of Hoxb13 in leukemia progression.
Dysregulation of Hoxb13 affects MA9-induced AML progression
We next examined whether high expression of Hoxb13 was an essential and common feature for MA9 AML progression. We found that Hoxb13 was significantly overexpressed in LSCs from MLL-r AML mouse models as compared with that in HSPCs (Fig. 7e). Importantly, HOXB13 exhibited increased expression in AML patient samples when compared with normal hematopoietic counterparts and the highest level in MLL-r patients when compared with other AML karyotypes (Supplementary Fig. 8a, b). Re-analysis of previously published ChIP-Seq data  revealed that the Hoxb13 locus exhibited high levels of H3K79me2 and H3K4me3 and low levels of the repressive H3K27me3 in L-GMP than in LSK and GMP (Supplementary Fig. 8c). In addition, a lower level of H3K9me3 was also observed in c-Kit+ cells from MA9 and MN3 AML mice when compared with controls (Supplementary Fig. 8d, e). Thus, we reasoned that dysregulation of the epigenetic markers may contribute to the increased Hoxb13 expression levels in MA9 LSCs. To further investigate the relationship of high Hoxb13 expression and MA9 AML progression, we knocked down Hoxb13 expression in MA9 leukemic cells (Fig. 7f). Indeed, knockdown of Hoxb13 reduced their colony formation ability (Fig. 7g) and prolonged the survival of MA9 AML mice (Fig. 7h). Taken together, these data suggest that Hoxb13 is epigenetically suppressed in normal HSPCs but activated in MA9 LSCs, and Suv39h1 functions in part by inactivation of Hoxb13 to delay leukemic progression.
Although the interest in developing leukemia therapies by targeting H3K9 methyltransferases is increasing , the role of Suv39h1 and its associated H3K9me3 modification in MLL-r AML remains unclear. In the present study, we provide insight into the significance of Suv39h1 in regulating MLL-r leukemia and LSCs. We found that the expression of SUV39H1 in AML blast cells and LSCs decreased as compared with their normal counterparts, and this correlated with overall outcomes of the disease. By restoration of the Suv39h1 expression, we demonstrated that this could decrease the number of functional LSCs and suppressed the development and progression of MLL-r AML. Correspondingly, we observed that suppression of Suv39h1 accelerated AML progression. Knockdown or inhibition of Suv39h1 led to the reduced H3K9me3 level, in the same trend as that Suv39h1 overexpression increased the H3K9me3 level. Our data thus strongly indicated Suv39h1 as a tumor suppressor for MA9 AML.
The expression of SUV39H1 was reported to decline with age in human and mouse HSCs, thus leading to a global H3K9me3 reduction and perturbed the heterochromatin function , and HSC aging increases the likelihood of progression to AML . Our study provides evidences that reduced SUV39H1 expression may cause the disruption of the hematopoietic homeostasis and lead to malignant hematopoiesis. In leukemia cells of AML patients, it has been reported that H3K9me3 occupancy is reduced in the promoters containing cis-binding sites for ETS and cyclic adenosine monophosphate response elements (CREs) for CREB/CREM/ATF1, and decrease of H3K9me3 is correlated with event-free survival in AML patients with t(8;21), t(15;17), inv(16), or complex karyotype . Our finding of decreased H3K9me3 level around TSS regions in MLL-r LSCs is in accordance with their observation of reduced H3K9me3 distribution in AML patients. Interestingly, they showed a correlation of decreased H3K9me3 with the CREB family in the study while we did not observe this correlation in our study, suggesting that there may be a different molecular mechanism underlying the differential distribution of H3K9me3 in distinct karyotypes of AMLs.
It has been reported that Suv39h-deficient mice spontaneously develop B-cell lymphomas at an increased frequency , and loss of Suv39h accelerates Ras- or Myc-driven tumorigenesis [43, 44]. Another study showed that increased Suv39h1 levels in Suv39h1 transgenic mice impaired the clonogenic transduction potential of oncogenes Ras/E1A in primary MEF and displayed a resistance to 7,12-Dimethylbenz[α]anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA)-induced skin carcinogenesis . These data, along with our findings demonstrate a tumor suppressive role of Suv39h1. However, SUV39H1 also participates in PML-RAR-  and EVI-1 -mediated transcriptional repression and acts as an oncogenic cofactor of these two fusion genes to induce hematological malignancies. Thus, the role of SUV39H1 in cancer may be context-dependent, and its specific roles in other subtypes of leukemia require further investigation.
A subset of H3K9 methyltransferases including Suv39h1, G9a, GLP, and SETDB1 were reported to participate in one complex and cooperate functionally in gene silencing . In consistent with this, our observation of the role of Suv39h1 in suppression of MLL-AF9 leukemia progression were in agreement with recent publication which reported a suppressive role of Setdb1 in MLL-fusion induced AML [24, 49]. Both studies revealed a decreased number of LSCs and increased apoptosis with H3K9 methyltransferase restoration. Interestingly, Suv39h1 and Setdb1 also shares some of the downstream targets, including reversing Hoxa9 and Meis1 signatures and suppressing MLL-AF9 target gene Six1. Nevertheless, pathway interaction analysis of DEG-enriched KEGG pathway revealed the reduction of metabolic process as one of the most prominent downstream effects of Suv39h1. Our recent study demonstrated that Six1 was a key transcription factor involved in leukemogenesis via regulation of LSC pools and the expression of glycolytic genes . In addition, the expression of Six1 was decreased in SUV-OE cells, which suggests that a potential mechanism of Suv39h1 in MA9 AML progression may also be partially mediated by Six1.
Notably, Suv39h1 displayed a unique role in regulation cell cycle, which was not observed in Setdb1 OE AML cells. Retinoblastoma protein (Rb) is sequentially phosphorylated by CycD/Cdk4/6 and CycE/Cdk2 and full phosphorylated Rb activates the E2F transcription factor family, thus promotes the G1-S transition . Previous study showed that Suv39h1 represses the expression of CycD1 to induce cell cycle arrest . Here in this study, we found down-regulated expression of cell cycle activation genes (Ccne1, Ccne2, Ccnd2 and E2F targets) as well as up-regulated expression of CDKi genes including p18, p21 family members p21 and p57 in SUV-OE cells. Thus, the decrease of S phase and the increase of G1 phase resulted by Suv39h1 overexpression were probably through coordinated regulation of G1/S transition related genes.
The recurrent mutation of G84E in the MEIS-interacting domain of HOXB13  has been reported to be associated with leukemia and other cancers in a clinical correlation research . Although a gain of function mechanism based on the lack of truncating mutations and the recurring nature of the G84E mutation has been suggested , the role of Hoxb13 in AML progression has not been defined. Notably, the basal expression level of Hoxb13 is very low in normal hematopoietic cells, but is upregulated in MA9 LSCs. We demonstrated here that Hoxb13 itself was epigenetically dysregulated in MA9 cells, and it was highly activated in LSCs when compared with normal HSPCs. Moreover, knockdown of Hoxb13 prolonged the survival of MA9 AML mice. Interestingly, although HoxB13 shRNA knockdown did not affect the expression of other HoxB family gene, yet we did observe the down-regulated expression levels of some HoxA family members, such as Hoxa9 and Hoxa10 (Supplementary Fig. 9a, b). Both HOXA9 and HOXA10 were reported to be highly expressed and significantly correlated with leukemia progression and/or maintenance . We reasoned that the lower expression levels of HOXA9 and HOXA10 probably were a reflection of slower progressing of leukemia rather than a HoxB13 shRNA non-specific knockdown effect on the HoxA family members. Our study thus showed that MLL-AF9 dependent expression of Hoxb13 could be suppressed by SUV39H1. Furthermore, restoration of Hoxb13 in SUV-OE AML cells accelerated the leukemia progression and increased the number of LSCs, suggesting Hoxb13 is a downstream effector of Suv39h1 in MA9 leukemia cells.
Herein, we demonstrate that Suv39h1 is significantly down-regulated in AMLs and could function as a tumor suppressor in MLL-rearrangement induced leukemia by regulating Hoxb13 and Six1, as well as Hoxa/Meis1 downstream signature genes. The underlying molecular mechanism mediated by the Suv39h1 in tumor suppression may provide a potential novel therapeutic targeting strategy for MLL-rearranged leukemia.
Materials and methods
Human samples and ethics
Primary human AML blasts and cord blood were obtained from an experimental pathology cell bank of the State Key Laboratory of Experimental Hematology (SKLEH) from Institute of Hematology and Blood Diseases Hospital (IHBD). Sample acquisition was approved by the Institutional Review Boards at the IHBD. CD34+ cells were enriched using a CD34 MicroBead Kit (Miltenyi, Bergisch Gladbach, Germany). Detailed information of patient samples was described previously .
Wild-type (WT) C57BL/6J mice were acquired from the animal facility of SKLEH. 8-week-old female mice were used for the experiments. Same batches of mice were randomly assigned to control and experiment groups. All animal procedures were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the IHBD, Chinese Academy of Medical Sciences.
Establishment of in vivo mouse models
MLL-AF9 (MA9) and MLL-NRIP3 (MN3) AML mouse models were established as described previously [55, 56]. MN3 was a relatively new MLL translocation reported by Balgobind et al. , and the mouse model was established in our hospital [56, 58]. Serial transplantation was performed to determine the self-renewal potential of the established MA9 leukemia cells, and P3 cells were used for all subsequent experiments for consistency. Full scan images of Western blots are supplied as Supplementary Fig. 10. The antibodies used for Western blots are listed in Supplementary Table 1.
Limit dilution assay
Series doses of leukemic cells were collected from the BM of suv39h1 overexpression (SUV-OE) or experimental eGFP+ control mice and subjected to a limiting dilution series. The frequencies of LSCs were calculated according to Poisson statistics using ELDA software .
RNA-seq and chromatin immunoprecipitation (ChIP)-seq
Enriched c-Kit+ cells from moribund SUV-OE or control mice were used. All procedures were performed as described previously . The data have been submitted to the NCBI Gene Expression Omnibus under accession number GSE115549 for RNA-seq and GSE132175 for ChIP-seq. The primers used in this study have been supplied in the Supplementary Table 2.
All experiments were repeated two to three time with the indicated numbers of mice. Sample size for each experiment was determined according to experience or the previously published papers. The investigator was not blinded during experiment or assessing the outcome. Distribution was tested using the modified Shapiro–Wilks method. When parameters followed Gaussian distribution, Student’s t test was used for two groups’ analyses and one-way ANOVAS was for comparing more than two groups to evaluate the statistical significance. We have statistically compared the similar variance between the groups as well. Analyses were carried out using the Prism version 7.01 software (La Jolla, CA, USA).
Tsai CT, So CW. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Oncogene. 2017;36:1753–9.
Zeisig BB, Kulasekararaj AG, Mufti GJ, So CW. SnapShot: acute myeloid leukemia. Cancer Cell. 2012;22:698–698. e691.
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391–400.
Fong CY, Morison J, Dawson MA. Epigenetics in the hematologic malignancies. Haematologica. 2014;99:1772–83.
Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94:984–93.
Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823–33.
Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 2012;7:283–301.
Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005;121:167–78.
Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14:355–68.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20:66–78.
Wong SH, Goode DL, Iwasaki M, Wei MC, Kuo HP, Zhu L, et al. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential. Cancer Cell. 2015;28:198–209.
Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood. 2011;117:4759–68.
Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21:473–87.
Rea S, Eisenhaber F, O’Carroll D, Strahl BD, Sun ZW, Schmid M, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000;406:593–9.
Djeghloul D, Kuranda K, Kuzniak I, Barbieri D, Naguibneva I, Choisy C, et al. Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation. Stem Cell Rep. 2016;6:970–84.
Sun D, Luo M, Jeong M, Rodriguez B, Xia Z, Hannah R, et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell. 2014;14:673–88.
Yang YJ, Song TY, Park J, Lee J, Lim J, Jang H, et al. Menin mediates epigenetic regulation via histone H3 lysine 9 methylation. Cell Death Dis. 2013;4:e583.
Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 2007;67:7275–83.
Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008;14:36–46.
Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015;21:335–43.
Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell. 2014;159:558–71.
Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sonderby CK, et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 2016;44:D917–24.
Ropa J, Saha N, Hu H, Peterson LF, Talpaz M, Muntean AG. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation. Haematologica. 2020;105:2273–85.
Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genom. 2009;2:18.
Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10:257–68.
Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818–22.
Muller-Tidow C, Klein HU, Hascher A, Isken F, Tickenbrock L, Thoennissen N, et al. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood. 2010;116:3564–71.
Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol. 2005;1:143–5.
Cherblanc FL, Chapman KL, Brown R, Fuchter MJ. Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol. 2013;9:136–7.
Cherblanc FL, Chapman KL, Reid J, Borg AJ, Sundriyal S, Alcazar-Fuoli L, et al. On the histone lysine methyltransferase activity of fungal metabolite chaetocin. J Med Chem. 2013;56:8616–25.
Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Reply to “Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases”. Nat Chem Biol. 2013;9:137.
Lai YS, Chen JY, Tsai HJ, Chen TY, Hung WC. The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells. Blood Cancer J. 2015;5:e313.
Chaib H, Nebbioso A, Prebet T, Castellano R, Garbit S, Restouin A, et al. Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia. 2012;26:662–74.
Li L, Liang Y, Kang L, Liu Y, Gao S, Chen S, et al. Transcriptional Regulation of the Warburg Effect in Cancer by SIX1. Cancer Cell. 2018;33:368–85. e367.
Chu Y, Chen Y, Li M, Shi D, Wang B, Lian Y, et al. Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia. Cancer Sci. 2019;110:2200–10.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A, et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood. 2006;108:297–304.
Wang QF, Wu G, Mi S, He F, Wu J, Dong J, et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood. 2011;117:6895–905.
Beebe-Dimmer JL, Hathcock M, Yee C, Okoth LA, Ewing CM, Isaacs WB, et al. The HOXB13 G84E Mutation is Associated with an Increased Risk for Prostate Cancer and other Malignancies. Cancer Epidemiol, Biomark Prev: Publ Am Assoc Cancer Res, Cosponsored Am Soc Preventive Oncol. 2015;24:1366–72.
Monaghan L, Massett ME, Bunschoten RP, Hoose A, Pirvan PA, Liskamp RMJ, et al. The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia. Front Oncol. 2019;9:705.
Peters AH, O’Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001;107:323–37.
Reimann M, Lee S, Loddenkemper C, Dorr JR, Tabor V, Aichele P, et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell. 2010;17:262–72.
Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436:660–5.
Petti E, Jordi F, Buemi V, Dinami R, Benetti R, Blasco MA, et al. Altered telomere homeostasis and resistance to skin carcinogenesis in Suv39h1 transgenic mice. Cell Cycle. 2015;14:1438–46.
Carbone R, Botrugno OA, Ronzoni S, Insinga A, Di Croce L, Pelicci PG, et al. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol. 2006;26:1288–96.
Goyama S, Nitta E, Yoshino T, Kako S, Watanabe-Okochi N, Shimabe M, et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia. 2010;24:81–8.
Fritsch L, Robin P, Mathieu JR, Souidi M, Hinaux H, Rougeulle C, et al. A subset of the histone H3 lysine 9 methyltransferases Suv39h1, G9a, GLP, and SETDB1 participate in a multimeric complex. Mol Cell. 2010;37:46–56.
Ropa J, Saha N, Chen Z, Serio J, Chen W, Mellacheruvu D, et al. PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of Hoxa9 and Meis1 in acute myeloid leukemia. Oncotarget. 2018;9:22123–36.
Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013;14:518–28.
Yang YJ, Han JW, Youn HD, Cho EJ. The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res. 2010;38:382–90.
Williams TM, Williams ME, Innis JW. Range of HOX/TALE superclass associations and protein domain requirements for HOXA13:MEIS interaction. Dev Biol. 2005;277:457–71.
Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia. 2013;27:1000–8.
Zheng Y, Zhang H, Wang Y, Li X, Lu P, Dong F, et al. Loss of Dnmt3b accelerates MLL-AF9 leukemia progression. Leukemia. 2016;30:2373–84.
Cheng H, Hao S, Liu Y, Pang Y, Ma S, Dong F, et al. Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood. 2015;126:1302–13.
Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet. 2014;46:287–93.
Balgobind BV, Zwaan CM, Meyer C, Marschalek R, Pieters R, Beverloo HB, et al. NRIP3: a novel translocation partner of MLL detected in a pediatric acute myeloid leukemia with complex chromosome 11 rearrangements. Haematologica. 2009;94:1033.
Guo H, Chu Y, Wang L, Chen X, Chen Y, Cheng H, et al. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia. Int J Cancer. 2017;141:324–35.
Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70–8.
We thank Drs Peng Wu and Xiaowei Xie for their assistance with the bioinformatics analysis of RNA-seq. We would also like to thank the experimental pathology cell bank facility for the storage of human patient samples of SKLEH from IHBD. This work was partially supported by the funds from the Ministry of Science and Technology of China (2017YFA0103402 and 2018YFA0107801), CAMS Innovation Fund for Medical Sciences (2016-I2M-1-017, 2017-I2M-3-015 and 2017-I2M-3-018), National Natural Science Foundation of China (81600136, 81670120, 81629001, and 81770105).
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chu, Y., Chen, Y., Guo, H. et al. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia. Oncogene 39, 7239–7252 (2020). https://doi.org/10.1038/s41388-020-01495-6
This article is cited by
Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion
The role of epigenetic modifications in Colorectal Cancer Metastasis
Clinical & Experimental Metastasis (2022)
Roles of ferroptosis in urologic malignancies
Cancer Cell International (2021)